Firefly Neuroscience And Bright Minds Advance Phase 1 Study With AI-Driven Data Analysis
Firefly Neuroscience And Bright Minds Advance Phase 1 Study With AI-Driven Data Analysis
Firefly continues to advance strategic partnerships and introducing technology into the market. The company recently announced a collaboration with Ketamine Clinics Los Angeles which will combine immersive digital mindfulness experiences with evidence-based therapies for conditions such as depression and PTSD. FireflyVR's platform, The Sanctuary, offers dynamic VR environments that engage patients through guided mindfulness exercises such as breathings, body scans and meditations.Firefly Neuroscience, Inc. (NASDAQ:AIFF) announced a collaboration with Bright Minds Biosciences Inc. (NASDAQ:DRUG) to analyze data from the first-in-human Phase 1 study of BMB-101, Bright Minds' lead compound for neuropsychiatric disorders and refractory epilepsy. Firefly employed its advanced AI-powered BNA technology to analyze the qEEG (Quantitative Electroencephalogram) data collected through EEG headsets provided by Zeto Inc.
Firefly Neuroscience, Inc.（納斯達克：AIFF）宣佈與Bright Minds Biosciences Inc.（納斯達克：DRUG）合作，分析BMb-101首個人體一期研究數據，該化合物爲Bright Minds在神經精神疾病和難治性癲癇中的主要化合物。Firefly運用其愛文思控股動力的BNA技術分析通過Zeto Inc.提供的EEG頭戴設備收集的qEEG（定量腦電圖）數據。
Why It Matters: The study demonstrated positive results, with subjects undergoing EEG recordings pre- and post-dose on days 1 and 7. The data showed that BMB-101 successfully achieved brain penetration, validating its targeting of 5-HT2C receptors. With the successful conclusion of the Phase 1 study, BMB-101 is now set to move into Phase 2 trials.
爲什麼這很重要：研究展示了積極的結果，受試者在第1天和第7天在服藥前後進行了腦電圖記錄。數據顯示BMb-101成功實現了對大腦的滲透，驗證了其針對5-HT2C受體的目標。隨着一期研究成功的結束，BMb-101現在將進入二期試驗。
Jon Olsen, CEO of Firefly, emphasized the impact of their AI platform on clinical studies, while Ian McDonald, CEO of Bright Minds, confirmed the company's plans to advance BMB-101 with an investigative new drug submission.
Firefly的CEO Jon Olsen強調了他們的人工智能平台對臨床研究的影響，而Bright Minds的CEO Ian McDonald確認了公司計劃通過提交新藥調查申請推進BMb-101。
A Growing Trend In The Market
市場中的增長趨勢
Firefly continues to advance strategic partnerships and introducing technology into the market. The company recently announced a collaboration with Ketamine Clinics Los Angeles which will combine immersive digital mindfulness experiences with evidence-based therapies for conditions such as depression and PTSD. FireflyVR's platform, The Sanctuary, offers dynamic VR environments that engage patients through guided mindfulness exercises such as breathings, body scans and meditations.
Firefly繼續推動戰略合作伙伴關係，並將技術引入市場。該公司最近宣佈與洛杉磯氯胺酮診所合作，將沉浸式數字正念體驗與基於證據的療法相結合，用於治療抑鬱症和創傷後應激障礙等症狀。FireflyVR的平台The Sanctuary提供動態VR環境，通過引導式正念練習，如呼吸、身體掃描和冥想，讓患者參與其中。
Cover image made with AI
封面圖片由人工智能製作
譯文內容由第三人軟體翻譯。
